Published in N Engl J Med on February 02, 1978
Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease. Blood (2011) 1.83
Receptor specific clearance by the reticuloendothelial system in chronic liver diseases. Demonstration of defective C3b-specific clearance in primary biliary cirrhosis. J Clin Invest (1978) 1.45
Inflammatory bowel disease associated circulating immune complexes. Gut (1980) 1.19
Clearance kinetics of soluble pre-formed immune complexes containing IgM antibodies in normal and decomplemented rabbits. Immunology (1981) 1.17
Alterations of T-cell subsets in primary biliary cirrhosis. Clin Exp Immunol (1982) 1.16
Clinical application of a new nephelometric technique to measure complement activation. J Clin Pathol (1983) 1.13
Deficiency of the autologous mixed lymphocyte reaction in patients with primary biliary cirrhosis. J Clin Invest (1980) 1.07
Immune complexes in human diseases: a review. Am J Pathol (1980) 1.05
Antibodies to a human liver membrane lipoprotein (LSP) in primary biliary cirrhosis. Gut (1980) 1.03
In vitro studies on the mechanism of increased serum IgM levels in primary biliary cirrhosis. Clin Exp Immunol (1985) 1.00
Monomeric (7S) IgM in chronic liver disease. Clin Exp Immunol (1979) 0.95
Evidence for defect of complement-mediated phagocytosis by monocytes from patients with rheumatoid arthritis and cutaneous vasculitis. Br Med J (Clin Res Ed) (1981) 0.94
Non-specificity of circulating immune complexes in patients with acute and chronic liver disease. Clin Exp Immunol (1980) 0.91
Role of plasmapheresis in primary biliary cirrhosis. Gut (1985) 0.91
Studies on the frequency and pathogenesis of liver involvement in rheumatoid arthritis. Ann Rheum Dis (1979) 0.91
In vitro studies of enhanced IgG synthesis in severe alcoholic liver disease. Clin Exp Immunol (1981) 0.91
Primary biliary cirrhosis and focal glomerulonephritis. Br Med J (Clin Res Ed) (1981) 0.88
Identification of biliary antigens in circulating immune complexes in primary biliary cirrhosis. Clin Exp Immunol (1980) 0.88
Complement activation in chronic liver disease. Clin Exp Immunol (1982) 0.86
D-penicillamine for primary biliary cirrhosis. Gut (1985) 0.83
Increased C1q binding and arthritis in primary biliary cirrhosis. Gut (1980) 0.83
Expression of adhesion molecules on mature cholangiocytes in canal of Hering and bile ductules in wedge biopsy samples of primary biliary cirrhosis. World J Gastroenterol (2005) 0.82
Mononuclear cell complement receptor blockade in primary biliary cirrhosis. Gut (1985) 0.80
Localisation of immunoglobulin on the liver cell surface in primary biliary cirrhosis. J Clin Pathol (1981) 0.80
Endothelial cell damage in primary biliary cirrhosis: influence of cholestasis and immunological mechanisms. Clin Exp Immunol (1992) 0.79
Clinical remission of membranous glomerulonephritis in primary biliary cirrhosis with cutaneous vasculitis. Br Med J (Clin Res Ed) (1984) 0.77
Circulating immune complexes in Indian childhood cirrhosis. Clin Exp Immunol (1982) 0.75
Circulating immune complexes in primary biliary cirrhosis: interactions with lymphoid cells. Clin Exp Immunol (1982) 0.75
Primary biliary cirrhosis-specific antimitochondrial antibodies in neonatal haemochromatosis. Clin Dev Immunol (2013) 0.75
Primary biliary cirrhosis. Br Med J (Clin Res Ed) (1982) 0.75
Polymorphonuclear leucocyte fluorescence and cryoglobulin phagocytosis in systemic lupus erythematosus. Clin Exp Immunol (1979) 0.75
An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science (1989) 18.79
Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol (1986) 10.92
Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell (1993) 5.99
Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science (1999) 5.09
Epithelioid cell cultures from rat small intestine. Characterization by morphologic and immunologic criteria. J Cell Biol (1979) 4.86
Glucose transport in isolated brush border membrane from rat small intestine. J Biol Chem (1973) 4.75
Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med (1989) 4.69
A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med (1990) 4.53
Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J Clin Invest (1998) 3.85
Human lymphocytes bearing T cell receptor gamma/delta are phenotypically diverse and evenly distributed throughout the lymphoid system. J Exp Med (1989) 3.70
Rat intestinal microvillus membranes. Purification and biochemical characterization. Biochem J (1968) 3.66
Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet (1997) 3.66
Distribution of T cell subsets in human lymph nodes. J Exp Med (1981) 3.64
A microtiter solid-phase radioimmunoassay for hepatitis A antigen and antibody. J Immunol (1976) 3.53
Location of T cell and major histocompatibility complex antigens in the human thymus. J Exp Med (1980) 3.41
Uptake and transport of macromolecules by the intestine. Possible role in clinical disorders. Gastroenterology (1974) 3.33
The pathogenesis of arthritis associated with viral hepatitis. Complement-component studies. N Engl J Med (1971) 3.31
Glycoproteins of 210,000 and 130,000 m.w. on activated T cells: cell distribution and antigenic relation to components on resting cells and T cell lines. J Immunol (1984) 3.26
Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med (1996) 3.04
Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. Immunity (1998) 2.92
Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol (1983) 2.90
Intraepithelial lymphocytes modulate Ia expression by intestinal epithelial cells. J Immunol (1984) 2.84
Intestinal uptake of macromolecules: effect of oral immunization. Science (1972) 2.80
Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med (1989) 2.77
A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med (1991) 2.68
BLAST-2 [EBVCS], an early cell surface marker of human B cell activation, is superinduced by Epstein Barr virus. J Immunol (1985) 2.66
Occupational exposure to hepatitis B virus in hospital personnel: infection or immunization? Am J Epidemiol (1982) 2.62
Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci U S A (1990) 2.59
Monoallelic expression of the interleukin-2 locus. Science (1998) 2.58
Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis. N Engl J Med (1982) 2.58
Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features. Gastroenterology (1983) 2.56
Stages of B cell differentiation in human lymphoid tissue. J Exp Med (1981) 2.49
Small intestinal permeability to macromolecules. Transmission of horseradish peroxidase into mesenteric lymph and portal blood. Lab Invest (1971) 2.46
Biogenesis of intestinal plasma membrane: posttranslational route and cleavage of sucrase-isomaltase. Proc Natl Acad Sci U S A (1979) 2.45
Immunohistologic and immunoelectron microscopic characterization of the mucosal lymphocytes of human small intestine by the use of monoclonal antibodies. J Immunol (1983) 2.44
Hepatitis C virus: epidemiology and transmission. Hepatology (1997) 2.43
Experimental infection of chimpanzees with hepatitis A virus. J Infect Dis (1975) 2.41
Increased uptake of amino acids and 2-deoxy-D-glucose by virus-transformed cells in culture. Proc Natl Acad Sci U S A (1972) 2.41
Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology (2001) 2.30
Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-myc. Proc Natl Acad Sci U S A (1993) 2.29
Purification of hepatitis A antigen from feces and detection of antigen and antibody by immune adherence hemagglutination. Infect Immun (1976) 2.27
Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science (1985) 2.22
Hepatitis A virus infection: new insights from seroepidemiologic studies. J Infect Dis (1978) 2.21
Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice. J Exp Med (1997) 2.21
Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol (2001) 2.20
Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology (1993) 2.20
Small intestinal absorption of horseradish peroxidase. A cytochemical study. Lab Invest (1971) 2.20
Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein. Virology (1996) 2.18
The pathogenesis of arthritis associated with acute hepatitis-B surface antigen-positive hepatitis. Complement activation and characterization of circulating immune complexes. J Clin Invest (1975) 2.13
Severe colitis in mice with aberrant thymic selection. Immunity (1995) 2.11
Roles of TH1 and TH2 cytokines in a murine model of allergic dermatitis. J Clin Invest (1999) 2.09
Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology (1975) 2.08
Glycoprotein composition of colonic mucosa. Specific alterations in ulcerative colitis. Gastroenterology (1984) 2.06
Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol (1986) 2.06
Composition of human colonic mucin. Selective alteration in inflammatory bowel disease. J Clin Invest (1983) 2.03
The immunopathology of experimental allergic encephalomyelitis. II. Endothelial cell Ia increases prior to inflammatory cell infiltration. J Immunol (1984) 2.02
Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology (1998) 2.01
Isovaleric acidemia: a new genetic defect of leucine metabolism. Proc Natl Acad Sci U S A (1966) 2.00
Evidence for a pathogenic role of a cell-mediated immune mechanism in experimental glomerulonephritis. J Exp Med (1978) 1.98
Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med (1997) 1.97
Posttranscriptional regulation of hepatitis B virus replication by the precore protein. J Virol (1997) 1.96
CD40-deficient mice generated by recombination-activating gene-2-deficient blastocyst complementation. Proc Natl Acad Sci U S A (1994) 1.96
Cloning and characterization of a novel hepatitis B virus x binding protein that inhibits viral replication. J Virol (1998) 1.96
Epstein-Barr virus superinduces a new human B cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts. Cell (1982) 1.95
The increasing incidence of hepatocellular carcinoma. N Engl J Med (1999) 1.92
Hepatitis B virus X protein is not central to the viral life cycle in vitro. J Virol (1992) 1.92
The native form and maturation process of hepatitis C virus core protein. J Virol (1998) 1.91
Cytokine imbalance and autoantibody production in T cell receptor-alpha mutant mice with inflammatory bowel disease. J Exp Med (1996) 1.91
Primary hepatocellular carcinoma. N Engl J Med (1991) 1.91
The prevalence of antibody to hepatitis A antigen in various parts of the world: a pilot study. Am J Epidemiol (1977) 1.86
Epithelioid hemangioma of bone. A tumor often mistaken for low-grade angiosarcoma or malignant hemangioendothelioma. Am J Surg Pathol (1993) 1.84
Intestinal antibodies. N Engl J Med (1977) 1.82
Distribution of antibody to hepatitis a antigen in urban adult populations. N Engl J Med (1976) 1.81
A new immunologic marker for human Langerhans cells. N Engl J Med (1981) 1.79
Decreased suppressor cell activity in inflammatory bowel disease. Clin Exp Immunol (1978) 1.75
Characterization of Langerhans cells by the use of monoclonal antibodies. Lab Invest (1981) 1.73
Epithelial glycoprotein is a member of a family of epithelial cell surface antigens homologous to nidogen, a matrix adhesion protein. Proc Natl Acad Sci U S A (1990) 1.72
In situ immunologic characterization of cellular constituents in lymph nodes and spleens involved by Hodgkin's disease. Blood (1982) 1.71
Influences of gamma interferon on synovial fibroblast-like cells. Ia induction and inhibition of collagen synthesis. J Clin Invest (1985) 1.71
Very low density lipoproteins in intestinal lymph: origin, composition, and role in lipid transport in the fasting state. J Clin Invest (1969) 1.71
Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci U S A (1997) 1.68
Normal serum ferritin concentrations in precirrhotic hemochromatosis. N Engl J Med (1976) 1.68
Circulating antibodies to bovine albumin in ulcerative colitis and Crohn's disease. Characterization of the antibody response. Gastroenterology (1976) 1.67
Macromolecular absorption. Mechanism of horseradish peroxidase uptake and transport in adult and neonatal rat intestine. J Cell Biol (1972) 1.66
Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis. Gastroenterology (1998) 1.65
Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci U S A (1991) 1.65
Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients. Blood (1990) 1.64
Hepatitis-associated antigen and hepatoma in the U.S. Lancet (1971) 1.64
Etiology of sporadic hepatitis B surface antigen-negative hepatitis. Ann Intern Med (1977) 1.63
Cell-mediated immunity in acute and chronic hepatitis. J Clin Invest (1975) 1.63
Naturally occurring missense mutation in the polymerase gene terminating hepatitis B virus replication. J Virol (1991) 1.61
Lymphocyte activation antigens. I. A monoclonal antibody, anti-Act I, defines a new late lymphocyte activation antigen. J Immunol (1984) 1.60
Epidemiology and clinical impact of hepatitis D virus (delta) infection. Hepatology (1985) 1.60